Liminal BioSciences Inc. PFSCF

short version

[skyhigh123]

Study Identification

Unique Protocol ID:	PBI-4050-CT-9-08
Brief Title:	Study to Evaluate Safety, Efficacy of PBI-4050 & Its Effect on Relevant Biomarkers in T2DM Patients With Metabolic Syndrome
Official Title:	A Phase 2, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Safety and Efficacy of PBI-4050 in Type 2 Diabetes Mellitus Patients With Metabolic Syndrome
Secondary IDs:

Study Status

Record Verification:	June 2018
Overall Status:	Active, not recruiting
Study Start:	May 29, 2017
Primary Completion:	September 2018 [Anticipated]
Study Completion:	September 2018 [Anticipated]
First Submitted:	March 10, 2017
First Submitted that met QC criteria:	March 15, 2017
First Posted:	March 16, 2017 [Actual]
Last Update Submitted that Met QC Criteria:	June 11, 2018
Last Update Posted:	June 12, 2018 [Estimate]

Sponsor/Collaborators

Sponsor:	ProMetic Pharma SMT Limited
Responsible Party:	Sponsor
Collaborators:

Oversight

U.S. FDA-regulated Drug:	No
U.S. FDA-regulated Device:	No
Data Monitoring:	No

Study Description

Brief Summary:

This is a Phase 2, multi-center, double-blind, placebo-controlled study of the safety and effect of PBI-4050 at doses ranging from 400 mg to 1200 mg on relevant biomarkers in subjects with inadequately-controlled T2DMS on stable background antidiabetic therapy.

Detailed Description:

This Phase 2 study will be performed by 15 sites in Canada. The total duration of study participation for each subject is approximately 20 weeks and comprises 6 study visits A total of approximately 268 subjects will be enrolled in the study and randomly assigned to one of the following 4 treatment groups: PBI-4050 400 mg PBI-4050 800 mg PBI-4050 1200 mg Placebo All subjects will receive the assigned study drug for 12 weeks.

Conditions

Conditions:	Type 2 Diabetes Mellitus Metabolic Syndrome
Keywords:

Study Design

Study Type:	Interventional
Primary Purpose:	Treatment
Study Phase:	Phase 2
Interventional Study Model:	Parallel Assignment
Number of Arms:	4
Masking:	QuadrupleParticipant, Care Provider, Investigator, Outcomes Assessor
Allocation:	Randomized
Enrollment:	268 [Anticipated]

Arms and Interventions

Arms	Assigned Interventions
Placebo Comparator: Placebo Daily dose of 6 capsules of placebo	Placebo Placebo soft gelatine capsule
Active Comparator: PBI-4050 400 mg Daily dose of 2 capsules of PBI-4050 and 4 capsules of placebo	Drug: PBI-4050 Soft gelatine capsule containing 200 mg of the active ingredient per capsule Placebo Placebo soft gelatine capsule
Active Comparator: PBI-4050 800 mg Daily dose of 4 capsules of PBI-4050 and 2 capsules of placebo	Drug: PBI-4050 Soft gelatine capsule containing 200 mg of the active ingredient per capsule Placebo Placebo soft gelatine capsule
Active Comparator: PBI-4050 1200 mg Daily dose of 6 capsules of PBI-4050	Drug: PBI-4050 Soft gelatine capsule containing 200 mg of the active ingredient per capsule

Outcome Measures

Primary Outcome Measures:
1.	To evaluate the safety of PBI-4050 400 mg, 800 mg, and 1200 mg as assessed by the number of subjects with abnormal laboratory values and/or adverse events that are related to treatment Number of subjects with abnormal laboratory values and/or adverse events that are related to treatment To evaluate the safety of PBI-4050 400 mg, 800 mg, and 1200 mg as assessed by the number of subjects with abnormal laboratory values and/or adverse events that are related to treatment [Time Frame: 4 months]
2.	To evaluate the efficacy of PBI-4050 400 mg, 800 mg, and 1200 mg Change from baseline on HbA1c levels To evaluate the efficacy of PBI-4050 400 mg, 800 mg, and 1200 mg [Time Frame: 3 months]
Secondary Outcome Measures:
3.	Change from baseline on diabetic biomarkers % reduction and/or increase of diabetic biomarkers such as fasting glucose, fasting insulin, fasting C-peptide Change from baseline on diabetic biomarkers [Time Frame: 3 months]
4.	Change from baseline on pro-inflammatory/inflammatory biomarkers % reduction and/or increase of biomarkers such as IL-6, IL-18, adiponectin Change from baseline on pro-inflammatory/inflammatory biomarkers [Time Frame: 3 months]
5.	To evaluate the effect of PBI-4050 on frequency of hypoglycaemia events Frequency of hypoglycaemia events To evaluate the effect of PBI-4050 on frequency of hypoglycaemia events [Time Frame: 3 months]

Eligibility

Minimum Age:	18 Years
Maximum Age:
Sex:	All
Gender Based:
Accepts Healthy Volunteers:	No
Criteria:	Inclusion Criteria: Subject is 18 years of age or older. Subject has signed written informed consent. Subject has a clinical diagnosis of T2DM with an HbA1c level between ≥ 7.5% and ≤ 10%. Subject has been receiving stable antidiabetic therapy (with or without basal insulin) for a minimum of 3 months before the screening visit. Subject is able and willing to self-monitor blood glucose level at home. Subject has a body mass index (BMI) of ≥ 27 kg/m2 and ≤ 45 kg/m2. Subject has metabolic syndrome, having at least 3 of the 5 risk factors. Exclusion Criteria: Subject is using prandial insulin or pre-mixed insulin in addition to oral hypoglycaemic agents for blood glucose control. Subject is taking basal insulin dose > 1.0 U/kg/day. Subject has recent or on-going infection requiring systemic treatment with an anti-infective agent within 30 days before screening. Subject has a history of pancreatitis or diabetic ketoacidosis. Subject has had at least one episode of severe hypoglycaemia in the past 12 months. Subject has evidence of significant cardiovascular disease within 3 months before screening. Subject has an estimated glomerular filtration rate (eGFR) < 60 mL/min/1.73 m2. Subject has uncontrolled hypertension. Subject has a diagnosis of rheumatic or inflammatory disease; or other autoimmune or inflammatory disease. Subject is concurrently taking and plans to routinely continue taking anti-inflammatory medications during the study. Subject is currently using medications for the indication of (or at the doses indicated for) weight loss. Subject has significantly elevated liver enzyme levels. History of malignancy of any organ system, treated or untreated, within the past 5 years other than basal or squamous cell skin cancer. Subject has a history of chronic alcohol or other substance abuse. Subject has a history of an allergic reaction to PBI-4050 or any of its excipients.

Contacts/Locations

Study Officials:	John Moran, MD Study Chair ProMetic Life Sciences Inc.
Locations:	Canada, Alberta
	C-Health Edmonton, Alberta, Canada
	Canada, Quebec
	Omnispec Clinical Research Mirabel, Quebec, Canada
	Canada
	LMC Clinical Research Inc. Barrie, Canada
	C-health - C-endo Division Calgary, Canada
	Centre de recherche clinique de Laval Laval, Canada
	Institut de Recherches Cliniques de Montreal (IRCM) Montral, Canada
	LMC Clinical Research Inc. Montral, Canada
	Manna Research Quebec City, Canada
	Synergy Medical Clinic Sherwood Park, Canada
	Manna Research Toronto, Canada
	Manna Research Vancouver, Canada

IPDSharing

Plan to Share IPD:

No

References

Citations:
Links:
Available IPD/Information: